Purchasing channels and precautions for Upatinib in China

Upadacitinib, a highly effective JAK1 selective inhibitor, has been widely used to treat immune-mediated diseases such as rheumatoid arthritis, atopic dermatitis (eczema), and ulcerative colitis. Since its approval in the Chinese market, domestic patients have been able to purchase this innovative drug in domestic hospitals and some designated pharmacies. However, as a prescription drug, the purchase of upadatinib must strictly follow the doctor's diagnosis and prescription.

In China, especially tertiary hospitals and large and medium-sized comprehensive hospitals, the supply of upadatinib is usually sufficient. The dermatology, rheumatology and immunology, gastroenterology and other departments of these hospitals always have upadatinib in stock to meet the medication needs of patients with different diseases. After the doctor evaluates the patient's condition and determines that upadatinib is a suitable treatment option, he or she will issue a prescription for the patient. The patient can purchase the drug at the hospital pharmacy with the prescription.

In addition, upadatinib has been included in the national medical insurance directory, and this policy has brought real economic benefits to patients. After being included in medical insurance, the out-of-pocket cost of upadatinib is significantly reduced, to approximately 2,000 yuan per month. The specific price and reimbursement ratio may vary depending on regional policies. Patients can consult their hospital pharmacy for detailed prices and reimbursement before purchasing.

In addition to hospital pharmacies, patients can also purchase upadatinib through some online medical platforms or designated chain pharmacies. These channels usually require patients to upload a doctor's prescription and pass online review before completing the purchase. This method provides patients with more drug purchasing options, and is more convenient especially for patients who need long-term medication but are inconvenient to go to the hospital frequently.

However, it is worth noting that although upadatinib is available in the domestic market, not all hospitals and pharmacies can provide the drug. Especially in some small and medium-sized cities where the supply of medicines is relatively limited, patients may face difficulty in purchasing medicines. Therefore, it is recommended that patients confirm with the hospital or pharmacy before going to the hospital or pharmacy to understand the inventory of medicines and inquire about the specific details of medical insurance coverage.